Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2705-2711

  Wei, Ge ^a   De dong, Cao ^a   Hui min, Wang ^a   Fang fang, Jie ^a   Yong fa, Zheng ^a   Yu, Chen ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Efficacy; Non small cell lung cancer; rhEndostatin; Safety; Systematic review

Indexed keywords

EID: 84858181864     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Azim HA, Elattar I, Loberiza F, et al (2009). Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer, 64, 194-8.
2. Cai L, Sun LC, Yang CY, et al (2007). Observation on the efficacy of Endostar combined with Chemotherapy in the treatment of non-small cell lung cancer. Chinese J Practical Int Med, 27, 1541-2.
3. Chen SJ, Huang HX, Li GS, et al (2008). Clinical study on endostar combined with vinorelbine and oxaliplatin in the treatment of advanced non-small cell lung cancer. J Hebei Medical University, 29, 819-21.
4. Fan QL, Kao J, Zhou WL (2008). Observation of the near efficacy on Injection of recombinant human vascular endothelial suppression combined NP in the treatment of advanced non-small cell lung cancer. Modern J Integrated Traditional Chinese Western Medicine, 17, 1170-1.
5. Folkman J (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 312, 594-607.
6. Han LC, Xing DJ (2009). Clinical Observation of Endostar Combined with TP Chemotherapy in the Treatment of Advanced Stage NSCLC. Chinese J Clinical Oncology, 36, 1205-7.
7. Huang C (2005). A study on relation of the level of CECs and efficacy of NP regimen with Endostatin in advanced NSCLC. Graduate Article, 1, 1-60.
8. Huang G, Chen L (2010). Recombinant human endostatin improves anti-tumor effi cacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 136, 1201-11.
9. Huang GS (2007). The efficacy of NP plus ENDOSTAR and chemotherapy in the treatment of non-small cell lung cancer. Henan J of Surgery, 13, 1-2.
10. Jin J (2009). Observation the efficacy of Chemotherapy Combined with Endostar in Patients with non-small cell lung cancer. China and Foreign Medical J, 7, 13.
11. Li W, Yin YM, Guo RH, et al (2008). Endostar combined with TP or GP regimen in 31 cases of advanced non-small cell lung cancer pafients. Chinese Clinical Oncology, 13, 797-9.
12. Liu H, Ao R, Zhang L, et al (2009). Combination of recombinant human endostatin and GP in the treatment of advanced non-small cell lung cancer. Chin J Prim Med Pharm, 16, 1574-5.
13. Liu J, Huang JZ, Quan JZ, et al (2009b). Clinical study of concurrent chemoradiotherapy combined with YH-16 in the treatment of local advanced non-small cell lung cancer. China Med Herald, 6, 253-4.
14. Liu J, Jin CL, Niu HR, et al (2009a). Observation of Endostar combined with weekly dose of Docetaxd regimen for non-small cell lung cancer. Medical Information Medicine and Surgery, 22, 506-8.
15. Ma JB, Yang JL, Li ZL, et al (2009). A randomized clinical trial of endostar combined with concurrent chemoradiotherapy in treatment of local advanced non-small cell lung cancer. J of Clinical Medicine in Practice, 13, 20-4.
16. Mu HY, Shen CY, Feng YL (2009). Clinical Observation on the Target Therapy of Rh-Endostin Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer. Chin J Lung Cancer, 12, 780-4.
17. O'Reilly MS, Boehm T, Shing Y, et al (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.
18. Pignon J, Tribodet H, Scagliotti G, et al (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.
19. Tang Z, Yu ZH, Yang ZX, et al (2009). Observation of rh-endostatin combined with TC regimen for non-small cell lung cancer. Chinese Clinical Oncology, 14, 341-3.
20. Te Velde EA, Vogten JM, Gebbink MF, et al (2002). Enhanced antitumor effi cacy by combining conventional chemotherapy with angiostatin or Endostatin in a liver metastasis model. Br J Surg, 89, 1302-9.
21. Wang KZ, Li CY, Li Y et al (2008). Clinical study of endu injection with NP chemotherapy in the treatment of advanced NSCLC. Ji Lin Med J, 29, 1059-60.
22. Wang WJ, Sun Y, Liu YY, et al (2005). Rults of randomized multicenter double-blind phase trial of rh-endtatin(YH-16)in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 8, 283-90.
23. Xiao M, Xue YY, Liu SQ (2009). Combination of Endostar and GP in the treatment of advanced non-small cell lung cancer. J Jiangsu University, 19, 348-9.
24. Xie YR, Huang JJ (2009). Clinical study on endostar combined with GP in the treatment of advanced non-small cell lung cancer. Chinese J Gerontol, 29, 2035-7.
25. Yang L, Wang WJ, Cui CX, et al (2005). Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Chinese J New Drugs, 14, 204-7.
26. Zhang T, Liu DH, Wang B, et al (2009). Latest Efficacy and Safety of YH-16 Combined with GP for Advanced Non-small Cell Lung Cancer. Chinese General Practice, 12, 969-70.
27. Zhu XS, Hu XW, Cao LJ, et al (2009). Clinical observation on the efficacy of Endostatin combined with chemotherapy in the treatment of non-small lung cancer. J Clinical Pulmonary Med, 14, 194-5.